ALK and non-small cell lung carcinoma: The lower rate of attrition reported for EGFR- and ALK-mutated NSCLC, i.e. approximately 30% in the real-world setting ( (46) and data of the authors about ALK+ NSCLC currently under review for publication), is probably attributable to the higher efficacy of targeted therapies and the lower biologic aggressiveness of these tumors (47, 48), as also suggested by the more frequent occurrence of oligoprogression in these tumors compared to non-oncogene-dependent NSCLC (49).